Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
https://doi.org/10.21518/2079-701X-2019-10-72-80
Abstract
Breast cancer steadily holds leading market positions in the malignancy morbidity and mortality pattern. The treatment of metastatic breast cancer remains an extremely topical issue, when its aim is not only to prolong the patient’s life, but also to preserve its quality. Due to advances in molecular diagnostics, it has become possible to use several new classes of drugs in recent times. CDK4/6 inhibitors that demonstrate high efficacy in the first-line therapy for luminal metastatic breast cancer is one of these groups. This review presents data from recent registration studies and a description of observations from our own clinical experience.
About the Authors
I. P. Ganshina
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Lead Researcher, Department of Chemotherapy and Combination Treatment of Malignant Tumours, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
D. A. Filonenko
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Lead Researcher, Department of Chemotherapy and Combination Treatment of Malignant Tumours, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
O. O. Gordeeva
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Oncologist, Department of Chemotherapy and Combination Treatment of Malignant Tumours, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
E. V. Lubennikova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Lead Researcher, Department of Chemotherapy and Combination Treatment of Malignant Tumours, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
I. V. Kolyadina
Federal State Budgetary Educational Institution of Additional Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Lead Researcher, Professor, Chair for Oncology and Palliative Medicine, Federal State Budgetary Educational Institution of Additional Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
A. A. Mescheryakov
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Lead Researcher, Deputy Director for Studies, Acting Head of Department of Chemotherapy and Combination Treatment of Malignant Tumours, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
References
1. Anderson W.F., Chatterjeen N., Ershler W. et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002 Nov;76(1):27-36.
2. Jacquet E., Lardy-Cleaud A., Pistilli B., Franck S. et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients. European Journal of Cancer. 2018;95:93-101.
3. Robertson J.F., Bondarenko I.M., Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997.
4. Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N Engl J Med. 2012;366:520–29.
5. The Nobel Prize in Physiology or Medicine 2001. Avaiable at: www.nobelprize.org/nobel_prizes/medicine/laureates/2001.
6. Finn R.S., Martin M., Rugo H.S., Jones S. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925.
7. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor- positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425. Epub 2016 Mar 3.
8. Hortobagyi G.N., Stemmer S.M., Burris H.A. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541.
9. Slamon D.J., Neven P., Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465. Epub 2018 Jun 3.
10. Tripathy D., Im S.-A., Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15.
11. Johnston S., Martin M., Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Breast Cancer. 2019;5:5.
12. Sledge G.W. Jr., Toi M., Neven P., Sohn J. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875. Epub 2017 Jun 3.
13. Tripathy D., Campos-Gomez S., Lu Y.-S., Franke F. et al. Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2- negative advanced breast cancer: MONALEESA-7 age subgroup analysis. SABCS. 2018;abstr.
14. Bardia A, Colleoni M, Campos-Gomez S, Jung KH et all. Ribociclib with endocrine therapy for premenopausal patients with hormone receptor- positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7. SABCS. 2018;abstr.
15. Жукова Л.Г., Ганьшина И.П., Гордеева О.О., Лубенникова Е.В. Рибоциклиб в 1-й линии терапии гормоночувствительного рака молочной железы. Современная онкология. 2018;2:38-41. [Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V. Ribociclib in the first-line therapy for hormone-sensitive breast cancer. Sovremennaya Onkologia. 2018;2:38-41.] (In Russ).
Review
For citations:
Ganshina IP, Filonenko DA, Gordeeva OO, Lubennikova EV, Kolyadina IV, Mescheryakov AA. Ribociclib for the treatment of hormone-positive HER2-negative breast cancer. Meditsinskiy sovet = Medical Council. 2019;(10):72-80. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-72-80
Views:
685
Email this article 